Regensburg Center for Interventional Immunology adopts
LUMICKS’ z-Movi® Cell Avidity Analyzer
Amsterdam, the Netherlands – May 27, 2021 – In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi® Cell Avidity Analyzer. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of chimeric antigen receptors (CARs) and accelerate the development of new CAR-T therapies.
The new instrument has been placed in the lab of Dr. Hinrich Abken, Professor and Chair for Genetic Immunotherapy at Regensburg University. Professor Abken is a pioneer in the design and development of CAR T cells for cancer malignancies. His current work is aimed at improving T cell targeting of cancer cells and at translating these strategies into clinical trials.
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021
News provided by
Share this article
Share this article
SAN DIEGO, May 11, 2021 /PRNewswire/ Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the first quarter ended March 31, 2021. We are encouraged by our continued progress in first quarter of 2021, building on the accomplishments from the prior year as we moved multiple programs forward to important inflection points, including our ongoing P-BCMA-101 and P-PSMA-101 CAR-T programs, on which we plan to provide further clinical updates later in the year, said Eric Ostertag, M.D., Ph.D., Chief Executive Officer of Poseida. Additionally, we intend to advance two INDs in our allogeneic CAR-T portfolio this year,
Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
E-Mail
The human genome contains roughly three million letters. On average, the genome sequences of any two people differ from each other by about one in every 1,000 letters. Yet different variants occur, from substituted letters to entire missing sections of DNA. Scientists from the Berlin Institute of Health (BIH) and the Regensburg Center for Interventional Immunology (RCI) have teamed up with Icelandic researchers to develop software that reliably and quickly identifies large deletions in ten-thousands of genomes simultaneously. The researchers have now published their findings in the journal
Nature Communications.
The human genome contains roughly three million letters and is distributed over 46 chromosomes. Yet the genetic variation from person to person is very small: the genome sequences of any two people differ from each other by about one in every 1,000 letters. Sometimes single letters are exchanged in the genome, while other times whole sections are moved around. M